Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2018

Study Completion Date

May 28, 2019

Conditions
Leiomyosarcoma
Interventions
DRUG

pazopanib + gemcitabine

pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle

Trial Locations (17)

13273

Institut Paoli Calmettes, Marseille

13385

CHU Timone, Marseille

14076

Centre François Baclesse, Caen

21034

Centre G.F Leclerc, Dijon

31052

Institut Claudius Regaud, Toulouse

33076

Institut Bergonié, Bordeaux

34298

Centre Val d'Aurelle Paul Lamarque, Montpellier

44806

Institut de Cancérologie de l'Ouest/Centre René Gauducheau, Nantes Saint Herblain

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

59020

Centre Oscar Lambret, Lille

63011

Centre Jean Perrin, Clermont-Ferrand

69373

Centre Léon Bérard, Lyon

75005

Institut Curie - Hôpital Claudius Regaud, Paris

76038

Centre Henri Becquerel, Rouen

92210

Institut Curie - Hopital René Huguenin, Saint-Cloud

94805

Institut Gustave Roussy, Villejuif

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

UNICANCER

OTHER

NCT01442662 - Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine | Biotech Hunter | Biotech Hunter